Matrix Capital Management

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Rivos is a startup focused on developing high-performance RISC-V computing solutions aimed at enterprise applications. The company specializes in manufacturing computing chips designed to provide efficient and powerful server systems, particularly for large language models and data analytics. Rivos offers a comprehensive RISC-V-based server platform that includes optimized processors, a data parallel accelerator, and an open software stack. This integration allows developers to enhance the performance, security, and overall cost-effectiveness of their existing workloads. Through its innovative technology, Rivos seeks to meet the growing demands of modern computing environments.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their challenging nature. The company operates a proprietary peptide-based platform designed to identify and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic and therapeutic applications, particularly focused on the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By enabling healthcare institutions to detect and address amyloid diseases at an earlier stage, AltPep aims to enhance human health outcomes and improve treatment options for patients suffering from these conditions.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Monod Bio is a life sciences company based in Seattle, Washington, focused on developing innovative biosensors for detecting proteins, toxins, antibodies, and other analytes. Founded in 2021, the company has created a biosensor platform that integrates binding, transduction, and amplification processes in a single step, allowing for the rapid and sensitive detection of a diverse array of target molecules. By leveraging recent advancements in computational protein engineering, Monod Bio has designed highly modular bio-sensing nanoswitches that facilitate cost-effective analytical assays. This technology aims to enhance the capabilities of the healthcare industry in biotechnology and medicine.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Talos Trading is an institutional technology infrastructure provider based in New York, co-founded in 2018 by Anton Katz and Ethan Feldman. The company specializes in offering a comprehensive crypto trading platform that supports the entire trading lifecycle, including price discovery, clearing, and settlement. Talos Trading provides solutions across spot, futures, and foreign exchange markets, leveraging institutional-grade technology to enable clients to stream real-time and request-for-quote prices. Additionally, the platform includes portfolio accounting tools and facilitates efficient settlement processes, connecting various participants within the crypto ecosystem.

Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.

Blockdaemon Inc. is a blockchain node management platform that enables businesses, enterprises, and developers to efficiently deploy and manage blockchain applications. Founded in 2013 and headquartered in Los Angeles, California, with additional offices in New York and Ireland, the company provides tools that allow users to manage nodes across more than 30 blockchain protocols, including Bitcoin, Ethereum, and Polkadot. Blockdaemon's solution is designed to be fully portable, enabling users to easily switch between networks and chains without the need for extensive configuration. The company also supports the blockchain developer ecosystem by offering expert dev-ops advice, facilitating smoother integration and deployment in the rapidly evolving blockchain landscape.

Solve Therapeutics is a biopharmaceutical company based in Belmont, California, founded in 2021. The company specializes in the development of first-in-class antibody-drug conjugates and bispecific therapeutics. With a team of experienced professionals, Solve Therapeutics aims to create innovative biopharmaceutical medicines that address significant unmet medical needs, ultimately enhancing patient outcomes and quality of life.

Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

Pramana, Inc. is a health technology company focused on transforming digital pathology for medical centers and pathology labs. It offers a comprehensive Digital Pathology as a Service (DPaaS) solution, which includes advanced whole slide imaging systems and a scalable software platform designed to enhance clinical workflows. By integrating the hardware capabilities from its predecessor, Spectral Insights, with nference's software expertise, Pramana provides a seamless service that enables pathologists to access high-quality images without operational challenges. Additionally, the company facilitates the use of AI-enabled decision support tools, enhancing the diagnostic process and ultimately improving patient care.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Bardavon Health Innovations, LLC specializes in healthcare technology and services specifically designed for managing workers’ compensation cases. Established in 2013 and based in Overland Park, Kansas, the company offers a comprehensive approach to workers’ compensation, facilitating the management of the entire employee lifecycle, from hire to retirement. Its technology connects employers with essential tools and information, enabling informed decisions regarding employees in injury risk positions. Bardavon’s solutions enhance communication among therapy providers, referral sources, and other stakeholders, while simplifying reporting, data tracking, and job analysis. The company’s product offerings include bNOTES, bNOTES Connect, Telerehabilitation, Clinical Consulting, Job Analysis, Post-Offer Employment Testing, and XRTS Effort Assessment. By providing real-time updates on patient status and justifying the need for therapy treatment, Bardavon aims to empower quality healthcare decisions through improved transparency and collaboration.

Blockdaemon Inc. is a blockchain node management platform that enables businesses, enterprises, and developers to efficiently deploy and manage blockchain applications. Founded in 2013 and headquartered in Los Angeles, California, with additional offices in New York and Ireland, the company provides tools that allow users to manage nodes across more than 30 blockchain protocols, including Bitcoin, Ethereum, and Polkadot. Blockdaemon's solution is designed to be fully portable, enabling users to easily switch between networks and chains without the need for extensive configuration. The company also supports the blockchain developer ecosystem by offering expert dev-ops advice, facilitating smoother integration and deployment in the rapidly evolving blockchain landscape.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

Emboline, Inc. is a medical device company specializing in the development of cardiovascular embolic protection devices for various cardiac procedures. The company has created innovative technologies such as the Emboline Complete Accessible Protection and the Emboliner catheter, which are designed to protect the arterial bed and cerebral arteries, respectively. These devices are particularly useful during percutaneous heart valve repair and replacement procedures, as they mitigate the risk of embolic events that can impact critical organs. Founded in 2011 and headquartered in Santa Cruz, California, Emboline serves diverse markets, including cardiac surgery, cardiopulmonary bypass, interventional cardiology, and interventional electrophysiology. As of early 2013, Emboline operates as a subsidiary of CardioLogical Solutions.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their challenging nature. The company operates a proprietary peptide-based platform designed to identify and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic and therapeutic applications, particularly focused on the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By enabling healthcare institutions to detect and address amyloid diseases at an earlier stage, AltPep aims to enhance human health outcomes and improve treatment options for patients suffering from these conditions.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Palleon Pharmaceuticals is a biotechnology company that develops therapeutics targeting glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in creating glycoimmune checkpoint inhibitors, a novel class of drugs designed to enhance immune response against cancer. By integrating insights from global leaders in glycoscience and human immunology, Palleon aims to provide a broader array of combination therapies that not only address cancer but also combat resistance to traditional immuno-oncology treatments. Additionally, the company develops therapies for inflammatory diseases, including autoimmunity and fibrosis.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Qrativ, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing an AI-driven healthcare platform, known as Darwin.ai, which focuses on identifying new treatments for rare diseases with unmet medical needs. By leveraging machine learning and artificial intelligence, Qrativ's drug purposing platform facilitates the discovery and development of new uses for existing molecules, aiming to provide patients with access to treatments that are currently unavailable in the market. The company collaborates with biotechnology and pharmaceutical firms to enhance their research and development efforts in addressing these critical healthcare challenges.

EpiBiome, Inc. is a precision microbiome engineering company focused on developing therapies to combat infectious diseases in humans and agriculture without relying on small-molecule antibiotics. Founded in 2013 and based in South San Francisco, California, EpiBiome offers innovative phage therapy solutions that target specific strains within the microbiome, addressing issues such as antibiotic resistance and providing alternatives to traditional antibiotics. The company’s therapies are designed to treat conditions like mastitis in dairy cows and infections caused by Escherichia coli in humans. EpiBiome employs advanced sequencing and bioinformatic processes to identify pathogenic bacteria and microbiome alterations that may lead to disease, facilitating patient recovery and enhancing health outcomes. As of mid-2018, EpiBiome operates as a subsidiary of Locus Biosciences, Inc.

nference, Inc. is a biotechnology company that specializes in an AI-based software platform designed to synthesize and analyze biomedical information. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference focuses on transforming unstructured and structured data from biomedical literature, electronic medical records, and real-world datasets. The company's technology utilizes neural networks to automate the extraction of insights from diverse datasets, facilitating advancements in drug discovery, life cycle management, and precision medicine. By providing comprehensive biological and clinical insights, nference aims to support pharmaceutical, biotechnology, and healthcare enterprises in overcoming challenges in drug development and clinical research, ultimately enabling the discovery of personalized diagnostics and treatments for patients.

Adaptive Biotechnologies Corporation is a commercial-stage company focused on advancing immune-driven medicine by leveraging the biology of the adaptive immune system to enhance disease diagnosis and treatment. Established in 2009 and headquartered in Seattle, Washington, the company offers a range of products and services, including its FDA-authorized clonoSEQ diagnostic test, which is designed for the detection and monitoring of minimal residual disease in patients with specific blood cancers, such as multiple myeloma and chronic lymphocytic leukemia. In addition to clonoSEQ, Adaptive Biotechnologies provides immunoSEQ research services and kits to support scientific research and the discovery of new diagnostic signals. The company also has a pipeline of clinical products aimed at diagnosing and managing various diseases, including cancers, autoimmune disorders, and infectious diseases. It maintains strategic collaborations with notable partners such as Genentech and Microsoft to develop innovative therapies and diagnostic tests.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Xero Limited is a New Zealand-based technology company that specializes in cloud-based accounting software designed for small and midsize enterprises, as well as accounting practices. Founded in 2006 and headquartered in Wellington, Xero offers a comprehensive suite of tools, including its core accounting software, a mobile app, and various solutions for accountants and bookkeepers, such as Xero HQ and Xero Practice Manager. The platform enables users to efficiently manage cash flow, invoicing, payments, and reporting through a subscription model with three tiers: starter, standard, and premium. Xero has established a strong market presence in New Zealand and Australia, successfully competing against traditional accounting software providers, and has expanded its services to other English-speaking countries, particularly the United Kingdom.

Tenor Networks, Inc. specializes in the development and manufacturing of optical switching systems and communications equipment. The company offers a range of products designed to enhance service intelligence for optical networks, including the TN250G, a Core MPLS Switch, and TEMPo, an element management platform. These products aim to improve the efficiency and management of optical communication systems, catering to the needs of modern network infrastructures.